Meeting
2023 ASCO Annual Meeting
Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.
Authors
Xiaomin Ou
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Xiaomin Ou , Xiayun He , Yu Wang , Xueguan Lu , Hongmei Ying , Dongmei Ji , Qinghai Ji , Chaosu Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04995120
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6068)
DOI
10.1200/JCO.2023.41.16_suppl.6068
Abstract #
6068
Poster Bd #
60
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.
First Author: Zhigang Liu
Poster
2022 ASCO Annual Meeting
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open-label, single-arm, phase Ib clinical trial.
First Author: Zhigang Liu
Poster
2021 ASCO Annual Meeting
Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial).
First Author: Lai-Ping Zhong
Poster
2021 ASCO Annual Meeting
The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.
First Author: Lingdi Zhao